News
Obintuzumab in Lupus Nephritis
In a post hoc analysis of the phase 2 NOBILITY trial, researchers found that treatment with obinutuzumab—an antibody that targets a protein expressed on certain immune cells—was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney con
ACR Convergence Preview (11.10.2023)
Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting.
Rheumatoid Synovium Characterized by Six Cell Type Phenotypes
Research work from the Accelerating Medicines Partnership (AMP: RA/SLE) Network, was published in Nature and more specifically characterizes RA synovium into several cell-type abundance phenotypes (CTAPs). Could CTAPs known disease features or more effective future therapies?
Arthritis Increased Amongst US Veterans
AI Identifies and Predicts Radiographic Change in Rheumatoid Arthritis
The American College of Rheumatology's (ACR) has published a preview of new research from ACR Convergence 2023 showing that AI and a deep learning system could accurately identify and predict joint space narrowing and erosions in hand radiographs of patients with rheumatoid arthritis (RA).
X-Rays Questioned for Diagnosing Early Rheumatoid Arthritis
Routine hand and foot radiographs in more than 700 patients being evaluated for rheumatoid arthritis (RA) made almost no difference in diagnosing the condition nor in predicting its course, Dutch researchers said.
Incidence, Microbiological Studies, and Factors Associated With Prosthetic Joint Infection After Total Knee Arthroplasty
A study of nearly 80,000 US veterans who underwent primary knee joint arthroplasty (TKA) showed the incidence of prosthetic joint infection (PJI) was highest in the first 3 months and remained elevated through 12 months compared with 12 months or more after surgery.
ACR Reacts to 2024 Medicare Physician Fee Schedule
The American College of Rheumatology (ACR) expressed concern that the conversion factor included in the Centers for Medicare and Medicaid Services (CMS) CY 2024 Medicare Physician Fee Schedule and Quality Payment Program final rule is insufficient to address rising inflation.
Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN Variants
A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved to be effective and without potentially allergic lung reactions.
Late Should Not Be Less (11.3.2023)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow.com.
H. Zoster Subunit Vaccine Efficacy with JAK Inhibitor Therapy
JAK inhibitors are known to increase the risk of herpes zoster infections between between 3-5 fold. Two recent reports suggest variable efficacy when JAK inhibitor (JAKi) treated patients are vaccinated with the recombinant herpes zoster subunit vaccine (RZV).
Oral Surveillance Study Alters Practice at VA
Safety risks found in a postmarketing trial with the Janus-associated kinase (JAK) inhibitor tofacitinib (Xeljanz) appear to have influenced prescribing patterns across the class for rheumatoid arthritis (RA) patients in the Veterans Affairs (VA) health system, researchers found.
Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitor Treatment of Skin Disorders
A JAMA systematic review and meta-analysis has showed the use of JAK inhibitors (JAKi) in immune-mediated inflammatory skin diseases was not associated with increased risk of all-cause mortality, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE) (compared to the placebo
Optimal Management of de Quervain Tenosynovitis
The treatment of de Quervain tenosynovitis (DQT) was examined by systematic review in JAMA, suggesting that local (US-guided) corticosteroid injection plus a thumb spica immobilization was associated with significant pain-relieving and functional benefits.
